Get the Stockscreener App
31.12
3.11%
-1.00
After Hours:
31.20
0.08
+0.26%
Moderna Inc stock is traded at $31.12, with a volume of 5.68M.
It is down -3.11% in the last 24 hours and up +0.10% over the past month.
See More
Previous Close:
$32.12
Open:
$32.04
24h Volume:
5.68M
Relative Volume:
0.53
Market Cap:
$12.42B
Revenue:
$5.06B
Net Income/Loss:
$-2.22B
P/E Ratio:
-5.3471
EPS:
-5.82
Net Cash Flow:
$-3.96B
1W Performance:
-4.72%
1M Performance:
+0.10%
6M Performance:
-52.67%
1Y Performance:
-70.80%
1-Day Range:
$31.02
$32.50
1-Week Range:
$31.02
$34.87
52-Week Range:
$29.25
$170.47
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
31.12 | 12.42B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Motley Fool Wealth Management LLC Cuts Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Jim Cramer Slams Moderna, Inc. (MRNA) as One of the Year’s Biggest Disappointments - Insider Monkey
Teacher Retirement System of Texas Purchases 12,651 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Has $25.79 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
KLP Kapitalforvaltning AS Invests $4.44 Million in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Vanguard Group Inc. Boosts Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Stake Lowered by Corient Private Wealth LLC - MarketBeat
Royal London Asset Management Ltd. Sells 178,991 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Is Moderna Stock A Sell With RFK Jr. Reportedly Eyeing Funds? - Investor's Business Daily
Jim Cramer: Moderna (MRNA) Blew It – But Their Cash Pile Could Save Them! - Insider Monkey
Moderna's Options Frenzy: What You Need to Know - Benzinga
Moderna, Inc. (MRNA): Among Stocks To Trade Without Tariffs And Interest Rate Fears - Insider Monkey
Trump administration at ‘war’ with mRNA technology: scientists alarmed vaccine skeptics could kill research - Inkl
As Vaccine Skepticism Mounts, Moderna’s Business Grows More Precarious - Barron's
Moderna chief brand officer Kate Cronin exits pharma giant - MM+M Online
Moderna, Novavax Shares Are Sliding Wednesday: What's Going On?Moderna (NASDAQ:MRNA) - Benzinga
Moderna, Novavax, and Pfizer shares fall amid U.S. vaccine fund cuts - Investing.com
Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of "Hold" by Analysts - MarketBeat
JPMorgan Chase & Co. Lowers Moderna (NASDAQ:MRNA) Price Target to $33.00 - MarketBeat
Northwest & Ethical Investments L.P. Grows Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Is Moderna, Inc. (MRNA) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Raymond James Financial Inc. Purchases New Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars? - Crowell & Moring LLP
Moderna, Inc. (MRNA): Among Stocks with Potential to Explode in 2025 - Insider Monkey
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks - Yahoo Finance
Avantax Advisory Services Inc. Invests $483,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Privium Fund Management B.V. Increases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
mRNA Patent Wars Update: The Plot Thickens with Key Rulings Expected in 2025 - IPWatchdog.com
Moderna price target lowered to $33 from $40 at JPMorgan - Yahoo Finance
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move - The Motley Fool
Wealthfront Advisers LLC Lowers Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
JPMorgan Cuts Price Target on Moderna to $33 From $40, Maintains Underweight Rating - Marketscreener.com
Proficio Capital Partners LLC Raises Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Swiss National Bank - MarketBeat
Skandinaviska Enskilda Banken AB publ Decreases Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
U.S. to spend $100M to develop bird flu vaccines, drugs (MRNA) (MRNA:NASDAQ) - Seeking Alpha
Moderna's Options: A Look at What the Big Money is Thinking - Benzinga
4 Things You Need to Know if You Buy Moderna Stock Today - Nasdaq
Intact Investment Management Inc. Invests $420,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Victory Capital Management Inc. Sells 168,512 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna. Why Anti-Covid19 Juggernaut Goes 'The Bloodmachine' for NASDAQ:MRNA by PandorraResearch - TradingView
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):